Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Information to Targeted Risk Assessment
The legacy of general health and science information has long served as a foundational resource for public awareness and clinical guidance, emphasizing preventive care, treatment protocols, and the dissemination of research findings. Within this broad context, discussions of medication safety and adverse effects were typically framed in terms of patient education and clinical risk communication. However, as the scope of health information expands, it becomes necessary to pivot from this general heritage toward more targeted concerns, particularly those arising in occupational settings. The transition from a broad health context to a focused examination of exposure risks is essential for understanding how certain substances may affect workers differently than the general population. In this regard, the consideration of bisphosphonate medications, such as Fosamax, and their association with osteonecrosis of the jaw (ONJ) represents a relevant case. While initial discussions centered on patient populations, the potential for occupational exposure during manufacturing or handling processes introduces a distinct dimension of risk assessment. This shift in perspective requires a careful reexamination of existing data to determine whether workplace exposure pathways warrant separate consideration from clinical use scenarios, thereby bridging the gap between general health information and occupational health concerns.
Bridging to Occupational Exposure: Fosamax and ONJ
Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and infection in the jaw area, with diagnosis typically based on visual examination and imaging. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current research suggests that bisphosphonates suppress bone turnover, which may impair the jawbone's ability to repair microdamage and respond to local stressors. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights that the jawbone has unique structural and cellular properties that may make it particularly susceptible to the effects of bisphosphonates.
Regarding the adequacy of warnings, the prescribing information for Fosamax includes a section on osteonecrosis of the jaw under warnings and precautions, noting that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also lists known risk factors and advises that discontinuation of bisphosphonate treatment may reduce risk for patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also notes that in placebo-controlled clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups, which may complicate the assessment of causation in individual cases (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, causation-related considerations include the presence of other risk factors, such as invasive dental procedures, cancer diagnosis, or concomitant therapies, which may contribute to the development of ONJ. The timeline between exposure and harm can range from days to months, and the risk increases with longer duration of use. Patients who develop severe symptoms should discontinue use, and most experience relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The recurrence of symptoms upon rechallenge with the same or another bisphosphonate suggests a drug-related effect in some individuals (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the evidence indicates that Fosamax use is associated with an increased risk of ONJ, particularly with longer duration of exposure and in the presence of other risk factors. The prescribing information includes warnings about this risk, and patients should be monitored for symptoms, especially if undergoing invasive dental procedures. The absolute risk remains low, but the potential for harm warrants careful consideration in clinical decision-making.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the link between Fosamax and osteonecrosis of the jaw?
Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption. A known adverse effect is osteonecrosis of the jaw (ONJ), a condition of exposed, non-healing bone in the jaw. Studies show that bisphosphonates suppress bone turnover, impairing jawbone repair. The risk increases with longer duration of use, especially beyond 2-3 years (https://pubmed.ncbi.nlm.nih.gov/39400702/).
What are the risk factors for developing ONJ while taking Fosamax?
Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, and pre-existing dental disease. The prescribing information lists these factors and advises that discontinuation may reduce risk for those needing dental surgery (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
How common is ONJ in Fosamax users?
ONJ is rare. A cohort study found absolute risk approximately 0.05% after 5 years of use. However, risk increases with duration: threefold higher after 2-3 years and eightfold higher after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.